Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

OTC Drug Reform & the CARES Act (Monographs & OMUFA) Webinar Sponsored by Reed Tech Oct. 21, 2020


WCG FDAnews

WCG FDAnews

Requirements around the OTC Monograph Reform, the Over-the-Counter Monograph User Fee Program (OMUFA), and the OTC Monograph Order Requests (OMORs) are about to become clearer. The FDA is expected to release additional guidance soon — and this free webinar can help one understand the next steps.

Through our experts, attendees will find out whether these changes will impact you and how one can navigate the shifts with expertise and savvy.

One particular change: With the passage of the Coronavirus Aid, Relief, and Economic Security (CARES) Act in March 2020, it is likely that all OTC drug manufacturers will need to pay a user fee, similar to those established under the Generic Drug User Fee (GDUFA) and Prescription Drug User Fee (PDUFA). The Act will also create new opportunities for innovation and help finalize the large number of pending monographs in many of the OTC drug therapeutic categories.

During this detailed conversation, medical device identification expert Gary Saner will speak with regulatory attorney Carolina M. Wirth about opportunities for growing an OTC portfolio and the complicated compliance issues that may arise during that effort. The pair will discuss OTC monograph reform, provide clarity on the industry’s current regulatory expectations and answer questions about how these requirements may impact a business.

We will cover:

The FDA’s OTC Monograph Reform, OMUFA, and OMOR


  • Understanding OTC Monograph Order Requests
  • The effect on existing OTC products
  • The impact on private label distributors
  • Examples of impacted products: hand sanitizers, sunscreens, topical analgesics, and CBD-infused products

OMUFA and the Coronavirus Aid, Relief, and Economic Security (CARES) Act

  • The consequences of the COVID-19 pandemic
  • Required user fees for all OTC drug manufacturers, similar to the Generic Drug User Fee and the Prescription Drug User Fee

Suggested Best Practices

  • Complying with the FDA’s new OTC regulatory framework
  • Advantages of a comprehensive, global strategy for regulatory compliance

Opportunities for Innovation

  • Exclusivity for OTC drug products

Working to expand the team’s OTC product manufacturing? Currently have pharmaceutical products that may be impacted by these shifting regulations? This free webinar will explain the expectations and possibilities of the adjusted OTC Monograph Reform coming our way. Join us for expert insights to help the team grow and succeed.

Webinar Details:

What You Need to Know:

OTC Drug Reform & the CARES Act (Monographs & OMUFA)

A Free FDAnews Webinar Sponsored by Reed Tech

Wednesday, Oct. 21, 2020, 11 a.m. – 12:00 p.m. EDT

http://info.fdanews.com/what-you-need-to-know

Easy Ways to Register:

Online: http://info.fdanews.com/what-you-need-to-know? free_webinar_source=HP

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations

Share article on social media or email:

KitoTech Medical and MyMedic Enter Into Partnership


We are excited to form a partnership with MyMedic, one of the leading first aid companies. They have both the expertise and commercial footprint to successfully launch microMend into this growing market, says Deon Miller, Chief Commercial Officer of KitoTech.

KitoTech Medical and MyMedic announce today that that they have formed a partnership to sell microMend’s consumer products for use in first aid and other emergency settings. Under terms of the agreement, KitoTech and MyMedic will collaborate to make and assemble the products. MyMedic will be responsible for selling the products as additions to its first aid kits, MedPacks™, and other supplies as well as stand-alone products. The first microMend products under the partnership are expected to be introduced onto the market in November.

“With its easy application and removal, microMend’s consumer products have been widely adopted by many people to treat lacerations and other serious wounds outside of hospitals and other medical facilities. Given this success, we believe that there is a great opportunity for microMend in the first aid market. We are excited to form a partnership with MyMedic, one of the leading first aid companies. They have both the expertise and commercial footprint to successfully launch microMend into this growing market,” says Deon Miller, Chief Commercial Officer of KitoTech.

David Barlow, CEO of MyMedic™, stated, “At MyMedic, we are continually curating the best, most innovative, and pro-grade First Aid supplies to the public. microMend is the perfect addition to the MyMedic arsenal of life-saving necessities. This product’s convenience and simplicity align so well with our core mission; to help people be as prepared as possible. We know the public will appreciate having access to microMend and all the benefits it provides.”

About microMend®

microMend consists of an array of miniature stainless steel staples (Microstaples) attached to an adhesive backing that combines the holding strength of a suture with the simplicity of applying a bandage. It represents an easy-to-use, time-saving, and cost-effective option for closing lacerations, skin tears, surgical incisions, and other wounds. microMend’s consumer products make it possible for people to treat lacerations at home, in the outdoors or elsewhere, and avoid ER or Urgent Care Clinic visits. microMend’s medical products are being used in the ER, Urgent Care Clinics, and Operating Rooms throughout the US.

About KitoTech Medical

KitoTech Medical is a medical device company spun out of the University of Washington that is using its patented Microstaple Technology platform to develop and commercialize products for wound closure and wound care. Additional product and company information can be found online at http://www.micromendskinclosure.com.

About MyMedic™

A family-operated First Aid Kits, Supplies, and Training company based on the objective to save lives, and is driven by a goal to prepare everyone with equipment and training for the unexpected emergency. Based out of Salt Lake City, Utah, MyMedic believes everyone should have instant access to a life-saving First Aid Kit. Visit MyMedic™ to learn more and follow @MyMedicofficial #stayalive #mymedic

Share article on social media or email:

Successful Dental Implant in a Patient with Osteopenia


Journal of Oral Implantology Volume 46 Issue 4

Journal of Oral Implantology Volume 46 Issue 4

Some of the risks they discussed in this case study included Bf duration, type, and administration method; and bone trauma during prosthetic installation.

Journal of Oral Implantology – Dental implants improve the quality of life of many people; however, side effects, such as osteonecrosis—bone tissue death—can occur in patients who take a group of drugs known as bisphosphonates (Bfs) as therapies for bone conditions. This, in turn, impacts the long-term survival rate of implants. Authors of a recent study in the Journal of Oral Implantology successfully treated a patient with low bone mass, a condition called osteopenia, and discussed treatment decisions they made after a thorough review of the literature.

Researchers and clinicians from Maringá, Brazil, were presented with a 53-year-old female patient who wanted dental implants to replace missing teeth. A medical history assessment revealed that the patient had osteopenia and took Bfs. To treat their patient most successfully, the authors reviewed the literature for rates and risks of osteonecrosis after dental implantation and possible ways to mitigate those risks. Some of the risks they discussed in this case study included Bf duration, type, and administration method; and bone trauma during prosthetic installation.

To prevent osteonecrosis in this patient, the authors chose three specific strategies. First, based on American Dental Association guidelines and previous literature, they suspended the patient’s Bf administration for 3 months before and after surgery. Second, the authors provided their patient with a 7-day treatment of clindamycin to prevent bacterial colonization, as some previous studies suggest that infection can enhance the risk of osteonecrosis. Third, they installed the Straumann bone level tapered implant to improve healing time of the bone around the implants. Overall, the patient received a total of three implants and no osteonecrosis has been reported thus far according to examinations and radiographic image analyses.

Additionally, the authors highlight that C-terminal telopeptide (CTX) values, a biomarker for bone remodeling, are often correlated with osteonecrosis risk. Although the patient in this case study had a low risk according to these values, the authors cite several articles in which the two cannot be correlated. Thus, they advise against using CTX as a conclusive measure to assess risk.

Through this detailed case study, it is clear that there are many decisions to be made when considering dental implant treatments for patients with bone disease and those who take Bfs. Therefore, clinicians should conduct a detailed review of medical records before conducting oral rehabilitation in patients who have underlying conditions and take medications.

Full text of the article “Oral Rehabilitation with Dental Implants and the Importance of a Preventive Evaluation for Osteonecrosis of the Jaws Associated with Medications,” Journal of Oral Implantology, is available at https://doi.org/10.1563/aaid-joi-D-19-00275.

###

About the Journal of Oral Implantology

The Journal of Oral Implantology is the official publication of the American Academy of Implant Dentistry and of the American Academy of Implant Prosthodontics. It is dedicated to providing valuable information to general dentists, oral surgeons, prosthodontists, periodontists, scientists, clinicians, laboratory owners and technicians, manufacturers, and educators. The JOI distinguishes itself as the first and oldest journal in the world devoted exclusively to implant dentistry. For more information about the journal or the society, please visit http://www.joionline.org

Share article on social media or email:

Newsweek Names Lakeside-Milam Recovery Centers The Best Treatment Center In Washington State


Lakeside Milam Recovery Centers, a leading provider of substance use disorder treatment services in Western Washington, has been recognized by Newsweek Magazine as one of the best addiction treatment centers in America and #1 in Washington State. Lakeside-Milam was one of only 200 treatment centers nationwide and 5 within the state of Washington to make the list.

“We are honored to receive this recognition from Newsweek,” said Carl Kester, CEO. “It reinforces our belief that at Lakeside-Milam we provide the finest addiction treatment available anywhere. It is a testament to the excellence of our staff and the evidenced based care that they provide. I am proud to work alongside them.”

In partnership with Statista, Newsweek utilized data provided by SAMHSA and surveyed thousands of addiction professionals, such as medical doctors, therapists, and counselors in selecting the best treatment providers.

The criteria included:

  • Quality of Care
  • Quality of Service
  • Quality of Follow Up Care
  • Accommodations and Amenities

“The fact that part of the criteria for this honor was the recommendation of physicians, therapists, and counselors outside of our organization makes this particularly meaningful for us,” said JP Liddle, Vice President of Business Development. “We are humbled by their continued trust in us to help their patients who suffer from a substance use disorder.”

ABOUT LAKESIDE-MILAM RECOVERY CENTERS:

With over 35 years of experience, Lakeside-Milam has served the Pacific Northwest by providing a full continuum of care. Guided by the book, Under the Influence, by Dr. James Milam and Katherine Ketcham, Lakeside-Milam has helped those struggling with substance abuse by providing quality structure, education, and support. Our goal is for people to recognize that recovery is possible and that they can achieve lasting recovery.

For the full list of treatment centers: https://www.newsweek.com/americas-best-addicition-treatment-centers-2020/washington

Share article on social media or email:

DDL Expands its Real Time Aging Capabilities at its Edison, NJ Testing Laboratory


“This additional space for Real Time aging expands DDL’s package testing offerings to better serve the needs of the pharmaceutical, medical device, and consumer goods industries on the east coast,” said Tamera Presler, General Manager, DDL, Inc.

DDL, Inc. announced today that it has expanded its ambient real time storage capabilities (i.e. 23C & 50% RH) with the addition of a new real time room with 3,500 cubic feet of storage area at its Edison, NJ testing laboratory.

Real-Time Aging provides the most accurate data to support the shelf life / expiry dating claims and determine the effects of aging on packaging and other materials. DDL offers a full suite of package testing including environmental conditioning, distribution simulation, integrity and strength testing, thermal performance, and shelf life testing at its Edison facility.

“This additional space for Real Time aging expands DDL’s package testing offerings to better serve the needs of the pharmaceutical, medical device, and consumer goods industries on the east coast,” said Tamera Presler, General Manager, DDL, Inc.

Please visit http://www.DDLTesting.com for more information or call 800-229-4235 if you would like to speak with one of our testing experts.

About DDL

DDL is an ISO/IEC 17025:2017 accredited, third party independent testing facility that offers expertise in package, container closure integrity, medical device and combination products testing primarily serving the life sciences industry. DDL’s testing laboratories are located in Eden Prairie, MN, Irvine, CA and Edison, NJ. Visit http://www.DDLTesting.com for more information about the services offered by DDL.

Share article on social media or email:

A New Study Reveals the Vital Importance of Online Reviews in Selecting Doctors


RepuGen – a healthcare reputation management solution, recently released results of a study on the importance of online reviews in the doctor selection process. The study underlines the importance of managing online reviews for patient acquisition and show that online reviews have become the main criteria for selecting a healthcare provider.

The study released by RepuGen highlights that online reviews have redefined the way patients choose their healthcare providers. While 79% of patients check online reviews when selecting a healthcare provider, 63% of patients read 10 or more reviews before deciding on a healthcare provider, and 30% say they will not visit a healthcare provider with poor reviews.

The results from the study were acquired from a survey that was conducted in July 2020, among 1,431 patients aged 18 and above across the United States. To better understand their review habits and online behavior, the patients faced a series of questions that included:

●    What is the most trusted review site?

●    How important are online reviews in the doctor selection process?

●    How many reviews are checked before selecting a provider?

●    Which review sites are checked the most?

●    Other factors that impact their selection process.

The key findings from the study were as follows:

1.    83% of patients below 60 and 59% of patients above 60 checked online reviews while selecting a healthcare provider

2.    76% of patients checked reviews on Google, and 37% of patients visited WebMD for reviews

3.    Since a high percentage of patients check reviews on Google, it ranked as the most trusted review site

4.    The recency of reviews counted to be necessary, as 62% of patients didn’t trust reviews that were older than 2 years and 36% of patients wouldn’t consider reviews that were older than a year.

5.     At least ten reviews on all review platforms are required, as 77% of young patients and 41% of older patients read ten or more reviews before deciding a healthcare provider

6.    Reviews are the second most essential factor patients consider when selecting a healthcare provider

To learn more about the study findings, read the complete Patient Review Survey 2020 here: https://www.repugen.com/patient-review-survey-2020

About RepuGen

RepuGen is a leading healthcare reputation management solution that helps practices grow through regular review generation, patient recovery, and retention. It is one of the only reputation management platforms tailored specifically for providers in the healthcare industry. The company believes that providing clients with the opportunity to take control of their online reputation will improve patient experience and the overall success of the healthcare business.

RepuGen was founded by Ajay Prasad, a digital marketer and online reputation evangelist whose company provides clients with a simple way to take control of their online reputation so that negative online reviews don’t incorrectly portray their practice.

Given that 80% of patients use reviews as part of their healthcare provider selection process, Repugen helps both the doctors and the patients find their perfect fit in each other.

RepuGen clients include MemorialCare, Golden State Dermatology, Cortica, Elevate Health, and many other well-known healthcare organizations in a various specialties.

For more information on RepuGen, please visit http://www.repugen.com

Share article on social media or email:

Esteemed Medical Doctors Partner with Top Scale Media Brand, 1MD, for Second Consecutive Year


Esteemed Medical Doctors Partner with Top Scale Media Brand, 1MD

We are honored that 1MD’s LiverMD is being recognized by the industry’s best-of-the-best in terms of product development, efficacy, and impact. Ziv Haklili, Co-Founder, Scale Media

For the second year in a row, esteemed board-certified doctors have signed on to join the 1MD Scientific Advisory Board (2020/2021) to lend expertise and guidance to the fast-growing, next-generation nutritional supplement brand, 1MD, powered by Scale Media. As experts in specific fields, ranging from rheumatology and immunology, to gastroenterology and urology, Dr. Adam Kreitenberg, Dr. Brian Greenberg, Dr. David Kahana, and Dr. Daniel I. Brison, respectively, will continue to support the brand in launching scientifically-proven, groundbreaking nutritional supplements that help people live healthier lives.

Dr. Adam Kreitenberg – A board certified rheumatologist who completed his internal medicine internship, residency, and rheumatology fellowship at the University of Southern California and Los Angeles County Medical Center

Dr. David Kahana – A board certified gastroenterologist and certified Physician Nutrition Specialist, trained at UCLA and who runs the Center for Digestive Health & Nutritional Excellence in Torrance, CA

Dr. Brian Greenberg – An immunologist, allergist, and pediatrician who received his medical degree from the University of Florida, and completed his residency and fellowship at UCLA

Dr. Daniel I. Brison – A board certified urologist who completed medical school at the State University of New York, and residency at the prestigious Endourology fellowship program at UCLA

“We are proud to have attracted a team of renowned medical doctors and thought leaders to our Scientific Advisory Board. Collectively, they represent over 70 years of clinical experience, which will bring significant expertise and insight to the advancement of 1MD’s product research and development,” said Scale Co-Founder Ziv Haklili. “Together, with their advice and guidance, we look to the future of pioneering the most therapeutic, clinical-strength health supplements on the market.”

This announcement of the 2020/2021 Scientific Advisory Boards comes on the heels of 1MD’s latest recognition honors as a NEXTY Award Finalist for “Best Condition-Specific Supplement” for 1MD LiverMD®, their clinical-strength liver support product, which includes patented, clinically-proven ingredients shown to promote optimal liver health.

“We are honored that 1MD’s LiverMD is being recognized by the industry’s best-of-the-best in terms of product development, efficacy, and impact,” said Ziv Haklili. “It underscores our commitment to formulating effective products based on integrity, innovation and excellence.”

Learn more about 1MD at https://1md.org/.

About 1MD:

1MD is one of five next-generation consumer lifestyle brands powered by Scale Media, an award-winning, tech-driven company in the beauty, health and wellness sector. Their mission is to innovate therapeutic, clinical-strength, physician-formulated health supplements that address America’s gravest health concerns. 1MD’s growing portfolio of 20+ clinically-proven products helps hundreds of thousands of people live happier, healthier lives. Learn more at 1md.org.

About Scale:

Headquartered in Los Angeles, California, Scale is a tech-driven direct-to-consumer company that builds and deploys next-generation CPG brands in the beauty, health and wellness industries. Through their proprietary eCommerce and digital marketing engine, Scale transforms consumers’ end-to-end online shopping experience while increasing brand loyalty and retention. Founded in 2013 by serial entrepreneurs Ben Flohr and Ziv Haklili, the company has rapidly powered and scaled concepts into multi-million-dollar consumer lifestyle brands, including 1MD, Hair La Vie, Simple Beauty, LiveWell, and Essential Elements. Today, Scale’s growing portfolio of 70+ products helps hundreds of thousands of people live healthier lives. The company is recognized as a Forbes’ Best Startup Employer for 2020, and is the 2020 recipient of the NBJ Leadership & Growth Award. Learn more at Scale.tech.

Scale Media Inquiries: Nicole Khandhar, Director of Operations, Scale Media, nicole.k@scale.tech

1MD Inquiries: Jennifer Fontaine, Creative Brand Manager, 1MD, jen.f@scale.tech

Share article on social media or email:

Catalent to Discuss Innovative Approaches to Achieving T-Cell Commercial Readiness at Upcoming Industry Conference


Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that Jesse Trekker, Ph.D., Business Director, Strategic Partnerships, Catalent Cell & Gene Therapy, will present at the Allogeneic Cell Therapies Summit, which will take place virtually on 26 – 28 October, 2020.

On Monday, 26 Oct., at 12:30 p.m. EST, Dr. Trekker will present “How to Commercially Scale T-cell Allogeneic Therapies”, where he will consider ways to overcome scale up challenges to progress successful development programs. Dr. Trekker will also discuss Catalent’s custom manufacturing methodology, and approaches to accelerate T-cell therapies to commercial readiness, so that patients can benefit sooner from innovative new therapies.

Dr. Trekker joined Catalent through its acquisition of MaSTherCell in 2020. Prior to joining MaSTherCell, he worked as a valorization researcher at Imec. Dr. Trekker holds a master’s degree in biomedical sciences, and a doctorate in biomedical technology, both from the University of Leuven (KU Leuven), Belgium.

For more information, please visit http://www.catalent.com/events/allogeneic-cell-therapies-summit-2020/.

About Catalent Cell & Gene Therapy

With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. When it acquired MaSTherCell, Catalent added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. An experienced partner, Catalent Cell & Gene Therapy has worked with industry leaders across 70+ clinical and commercial programs.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

The Ethical and Business Demands for Clinical Trial Transparency, Upcoming Webinar Hosted by Xtalks


By repurposing clinical trial information instead of letting it languish in a database, sponsors can turn “patient engagement” from a buzzword to an actionable business practice.

When we think of transparency in the pharmaceutical industry, our thoughts often focus on transparency in drug pricing. However, regulatory and corporate obligations also call for disclosure of clinical trial information. Public opinion of the pharmaceutical industry has plummeted in recent years. Today, the coronavirus pandemic has placed pharmaceutical companies under a global microscope. Industry watchdogs, patient advocacy organizations and the public in general are demanding greater transparency. This provides clinical trial sponsors the opportunity to make transparency a priority and improve the reputation of their brands and the industry as a whole.

Clinical trials produce a wealth of data, much of which can be repurposed to the sponsor’s advantage. For example, this data can be synced to the search engine of a clinical trial finder website, can help better match patients to clinical trials, and can be shared with other researchers upon request. By repurposing clinical trial information instead of letting it languish in a database, sponsors can turn “patient engagement” from a buzzword to an actionable business practice.

The COVID-19 pandemic brings to light the ethics of getting information out more quickly than strictly required by regulation, or more thoroughly, as medical professionals, media and the general public are all looking for effective and safe treatments. The pandemic also has shown that collaboration is possible within the pharmaceutical community. Drug makers are partnering with one another, as well as with academic institutions, uniting to develop a vaccine.

Join Thomas Wicks, Chief Strategy Officer, TrialScope and Francine Lane, Vice President of Global Transparency, TrialScope in a live webinar on Friday, October 23, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Beyond Compliance: The Ethical and Business Demands for Clinical Trial Transparency.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

DuPont Research Demonstrates Impact of Strain Specificity on Human Milk Oligosaccharide Utilization


News Image

“It is essential to understand the numerous interactions affecting our health throughout life which can eventually be used as a guide to develop products for supplementation,” stated the study’s lead author, Bryan Zabel, assistant scientist, DuPont Nutrition & Biosciences.

Continuing its leading research on human milk oligosaccharides (HMOs), DuPont Nutrition & Biosciences released the findings of a new study demonstrating the importance of probiotic strain specificity, even within a sub-species, when related to efficient utilization of Human Milk Oligosaccharides (HMOs).

Several species of Bifidobacterium have been shown to utilize HMOs, but little work has been done to study utilization variations within the species or sub-species. This study examined two strains of B. infantis, a prevalent species in the guts of breastfed infants. The study found that B. infantis Bi-26™ has a unique strategy to quickly utilize 2-Fucolsyllactose (2’-FL), 3’-FL and difucosyllactose (DFL) which results in faster growth, unique metabolite production, and a distinct global gene transcription response when compared to the type strain ATCC 15697 (reference strain for the B. infantis subspecies).

“We are excited to further the research on defining the individual strain’s role within the complex system of the microbiome. It is essential to understand the numerous interactions affecting our health throughout life which can eventually be used as a guide to develop products for supplementation,” stated the study’s lead author, Bryan Zabel, assistant scientist, DuPont Nutrition & Biosciences.

“Our research helps us to further understand the interactions between probiotic strains and HMOs and allows us to develop targeted health products,” said Dr. Ratna Mukherjea, Technical Fellow and Technology & Innovation Leader, Specialized Nutrition, DuPont Nutrition & Biosciences. “This study marks a significant advancement in DuPont’s work in early life nutrition.”

You can read the full study at http://www.nature.com/articles/s41598-020-72792-z.

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: http://www.dupontnutritionandbiosciences.com.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety. More information can be found at http://www.dupont.com/.

# # #

10/12/20

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

Share article on social media or email: